Should I Buy ANRO? ANRO 2026 Analysis

Should You Buy Alto Neuroscience Inc (ANRO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

15.220

1 Day change

7.87%

52 Week Range

20.910

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: price action is consolidating with no proprietary buy signals and no near-term news catalyst.
Options flow is very bullish (heavy call skew), but hedge funds have been increasing selling materially—mixed positioning reduces conviction for an immediate entry.
Better setup would be either (1) a clean breakout and hold above ~17.66 (R1) or (2) a pullback toward ~14.83 (S1) for a clearer risk/reward; at 16.16 the stock sits in the “middle” of the range.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Pre-market price 16.16 is slightly below the pivot (16.247), suggesting the stock is currently trading just under the near-term decision level.
MACD histogram -0.195 (below zero) but “negatively contracting” → bearish momentum is fading, yet not reversed.
RSI(6) ~49.45 → neutral; no overbought/oversold edge.
Moving averages converging → consolidation/indecision rather than a trend.
Key levels: Support S1 14.829 (then S2 13.954); Resistance R1 17.664 (then R2 18.539). A move above R1 would improve the long bias; losing S1 would worsen it.
Pattern-based forward stats provided: modestly flat near-term (next day/week) with slightly negative next-month bias (-0.88%).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Very call-skewed (OI P/C 0.34 and Volume P/C 0.02) → traders are positioning bullishly/for upside.
Activity spike: today’s option volume vs 30D avg ~501.86% and today vs OI avg ~214.6% → unusual attention/positioning.
Volatility: 30D IV ~133.72 vs historical vol ~209.37; IV rank ~12.06 and IV percentile ~32.8 → options are elevated in absolute terms, but not “maxed out” versus recent history.
Interpretation: flow is bullish, but in a catalyst-driven biotech this can be speculative positioning rather than confirmed trend-following.

Technical Summary

Sell

Buy

Positive Catalysts

- Catalyst-rich 2026 setup highlighted by multiple analysts: Phase II readouts expected across programs (ALTO-101 Q1 2026; ALTO-300 mid-2026; ALTO-100 2H 2026; timelines for ALTO-207 accelerated per Jefferies).
- Analyst sentiment has been strongly positive with rising price targets (BTIG initiation Buy; Baird/Jefferies target raises).
- Options market positioning is decisively bullish (heavy call participation).

Neutral/Negative Catalysts

- No news in the past week → lack of an immediate event-driven catalyst to force a near-term repricing.
- Hedge funds are selling, with selling amount up ~159.2% over the last quarter → institutional flows a headwind.
- Biotech financial profile remains loss-making with ongoing burn (no revenue; widening losses), which can pressure sentiment between clinical updates.
- Technical posture is neutral-to-slightly-bearish (MACD below zero, price below pivot) with no proprietary buy signals today.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (no change YoY) → still pre-commercial.
Net income: -14.181M, down ~15.50% YoY → losses widened.
EPS: -0.52, down ~16.13% YoY → profitability trend deteriorated.
Takeaway: fundamentals are primarily driven by clinical progress and financing expectations, not operating revenue growth yet.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst trend (Nov 2025): clearly improving/constructive.
2025-11-12 Jefferies: Buy; price target raised to $25 from $15 (cites multiple 2026 data catalysts and accelerated timeline for ALTO-207).
2025-11-13 Baird: Outperform; price target raised to $22 from $16 (post-Q3 update; expects catalyst-rich 2026).
2025-11-17 BTIG: Initiated with Buy; $27 target (precision psychiatry + biomarker-driven subgroups; expects near-term validating readouts).
Wall Street “pros” view: large upside to targets driven by upcoming clinical data and platform approach.
Wall Street “cons” view (implied by context/flows): between catalysts the stock can drift; execution/data risk is the core swing factor, and hedge fund selling suggests some skepticism on timing/near-term upside.

9 Analyst Rating

Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 32.86 USD with a low forecast of 16 USD and a high forecast of 50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 14.110

Low

Averages

32.86

High

Current: 14.110

Low

Averages

32.86

High

BTIG

Thomas Shrader

initiated

$27

AI Analysis

2025-11-17

Reason

BTIG

Thomas Shrader

Price Target

$27

AI Analysis

2025-11-17

initiated

Reason

BTIG analyst Thomas Shrader initiated coverage of Alto Neuroscience with a Buy rating and $27 price target. The company is focused on next-generation drugs in psychiatry, including major depressive disorder and treatment-resistant depression, the analyst tells investors in a research note. The firm says each of Alto's programs is supported by "innovative" biomarkers to define subgroups of patients most likely to respond to the specific mechanism of the drug. It sees "several near-term validating" data readouts for the company.

Baird

Outperform

maintain

$16 -> $22

2025-11-13

Reason

Baird

Price Target

$16 -> $22

2025-11-13

maintain

Outperform

Reason

Baird raised the firm's price target on Alto Neuroscience to $22 from $16 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results which suggests clinical progress continues ahead of a catalyst-rich 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANRO

Unlock Now

ANRO Should I Buy

ANRO Should I Buy

Should You Buy Alto Neuroscience Inc (ANRO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch